The 1st CBA Biomarker and Diagnostics Study Group Meeting: Recap
Gaithersburg, MARYLAND, May 6, 2018.
The launch of CBA Biomarker and Diagnostic Discussion Group has taken place. 19 scientists and professionals from Washington DC and Philadelphia areas attended the kick-off meeting for a study group to facilitate the applications of the biomarkers and innovative diagnostic technologies in precision medicine.
In the Spring of 2018. Dr. Harry Yang, Dr. Judy Yu, Dr. Peixuan Zhu and Dr. Chuanhua Julia Xing and the CBA president elected, Dr. Frank Li formed the idea of a CBA Biomarker and Diagnostics Study Group to facilitate the scientific learning, education, and exchange in areas of research achievements, technology improvements, clinical trial development, regulatory policy and guideline updates etc. related to precision medicine. The establishment of this group should strengthen and advance scientific discussion and communication in area of biomarker and companion/complementary diagnostics among the scientists, clinicians and biopharmaceutical communities in Washington D.C. area.
The mission of this group is aligned with the CBA’s mission to promote the precision medicine and biomarker strategy among regions by taking advantage of the rich resources in this region. With the rapid advancement of the genomics and sequencing technology, precision medicine became a hot topic in the biomedical research and development field, where precision diagnosis plays the fundamental role for the precision medicine and P4 medicine era.
At the 1st CBA Biomarker and Diagnostics Discussion Group Meeting held on Saturday, May 6th, 2018, 19 scientists and professionals from NIH, Johns Hopkins, MedImmune, AstraZeneca, GeneDx, PacBio, XPrecision and other biotech companies joined onsite or online. One member of the group drove 2hrs from Philadelphia to attend the meeting. All attendees are very passionate for this leading topic on precision diagnosis. The CBA President-Elect Dr. Frank Li opened up the meeting with enthusiasm, “Congratulations! This is the first study group focused on biomarkers under CBA umbrella. It is a new experiment of exploring the way of development for a non-profit and professional organization. I hope each of you will enjoy studying together as a group and share knowledge and expertise for your experience.” He also pointed out that the discussion content of this group will only include the knowledge in the public domain. The rest of the meeting focused on self-introduction by each attendee. The background introduction of each individual led to enthusiastic conversations in work experience, technical and business expertise.
The discussion was also covered the upcoming 23rd CBA Annual Conference on June 9th 2018.Many world-class experts such as Prof. Lieping Chen, Dr. Richard Pazdur, Dr. Gang Wang, Dr. Bing Yao, etc. will talk about their brilliant scientific achievement in Immuno-Oncology, Drug Discovery and Development, Advanced Translational Medicine, AI & Big Data in Biopharmaceutical and Healthcare, etc. which include the new trend and progresses in Biomarker and Diagnostics area. All members are warmly expecting another great and fruitful conference with a high enthusiasm.
Future activity plans were also discussed such as seminar/webinar, publications and resources sharing, projects and collaboration, communication/outreaching, regulation and legal guidelines, etc., which will tentatively open to all CBA active and lifetime members.
The group members are now working on finalizing the short-term and mid-term goals and topics to discuss, scheduling monthly meeting agendas and speakers, setting up information sharing space etc. Stay tuned for upcoming progress!
–Yixing Han reports
Source: ©CBA- Biomarker and Diagnostics Study Group